Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery

Peptides

Volumn 31, Issue 1, 2010, Pages 184-193

  Tan, Mei Lin ^a   Choong, P F M ^a,b   Dass, C R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Drug delivery systems; Peptides; Proteins; Therapy

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA CYCLODEXTRIN; BONE MORPHOGENETIC PROTEIN 2; BOVINE SERUM ALBUMIN; CALCITONIN; CARBOMER; CHITOSAN; COLLAGEN SPONGE; DAUNORUBICIN; DOXORUBICIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HETASTARCH; INSULIN; LIPOSOME; NANOCARRIER; NEUROTOXIN; OUTER MEMBRANE PROTEIN; POLYGLACTIN; PROTIRELIN; RHODAMINE; TETRAPEPTIDE; TUBULYSIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTICONVULSANT ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BLOOD BRAIN BARRIER; BONE DEVELOPMENT; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CHLAMYDIASIS; COLON CARCINOMA; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RESEARCH; DRUG SAFETY; EYE INFLAMMATION; HUMAN; INTRACTABLE EPILEPSY; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEIZURE; SOLID TUMOR; SPINAL CORD INJURY;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; PEPTIDES; PROTEINS;

EID: 72749093756     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.10.002     Document Type: Review

References (63)

1. Aguado M.T., and Lambert P.H. Controlled-release vaccines-biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 184 (1992) 113-125
2. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 5665 (2004) 1818-1822
3. Balasse E., Odot J., Gatouillat G., et al. Enhanced immune response induced by BSA loaded in hydrozyethylstarch microparticles. Int J Pharm 353 1-2 (2008) 131-138
4. Boden S.D., Zdeblick T.A., Sandhu H.S., et al. The use of rhBMP-2 in interbody fusion cages. Spine 25 3 (2000) 376-381
5. Boyne P.J. Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am 83 (2001) s146-s150
6. Builders P.F., Kunle O.O., Okpaku L.C., et al. Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin. Eur J Pharm Biopharm 70 3 (2008) 777-783
7. Camelo S., Lajavardi L., Bochot A., et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis 13 (2007) 2263-2274
8. Cao L., Liu L., Chen Z.Y., et al. Olfactory ensheathing cells genetically modified to secrete GDNF to promote spinal cord repair. Brain 127 3 (2004) 535-549
9. Cheng H., Wu J.P., and Tzeng S.F. Neuroprotection of glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury. J Neurosci Res 69 3 (2002) 397-405
10. Cheng Q.Y., Feng J., Chen J., et al. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm Drug Dispos 29 8 (2008) 431-439
11. Chiappetta D.A., Carcaboso A.M., Bregni C., et al. Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 10 1 (2009) 1-6
12. Cho Y.W., Park S.A., Han T.H., et al. In vivo tumour targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 28 6 (2007) 1236-1247
13. Christensen D., Korsholm K.S., Rosenkrands K.S., et al. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 6 (2007) 785-796
14. Dass C.R., Walker T.L., Burton M.A., and DeCruz E.E. Enhanced anticancer therapy mediated by specialised liposomes. J Pharm Pharmacol 49 (1997) 972-975
15. Davis S.N., and Granner D.K. Insulin, oral hypoglycaemic agents, and the pharmacology of endocrine pancreas. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddeon R.W., and Gilman A.G. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. (1996), Mc-Graw Hill, New York 1487-1517
16. Devy J., Balasse E., Kaplan H., et al. Hydroxyethylstarch microcapsules: a preliminary study for tumour immunotherapy application. Int J Pharm 307 2 (2006) 194-200
17. Foust K.D., Flotte T.R., Reier P.J., et al. Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat. Hum Gene Ther 19 1 (2008) 71-82
18. Frokjaer S., and Otzen D.E. Protein drug stability: a formulation challenge. Nat Rev 4 (2005) 298-306
19. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42 5 (2003) 419-436
20. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmcol 533 (2006) 182-194
21. Hajos F., Stark B., Hensler S., et al. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm 357 (2008) 286-294
22. Hansen J., Jensen K.T., Follmann F., et al. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. JID 198 1 (2008) 758-767
23. Hirano S. Chitin and chitosan as novel biotechnological materials. Poly Int 48 (1999) 732-734
24. Jain A.K., Chalasani K.B., Khar R.K., et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 15 6 (2007) 417-427
25. Jones A.L., Bucholz R.W., Bosse M.J., et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects: a randomised, controlled trial. J Bone Joint Surg Am 88 7 (2006) 1431-1441
26. Jungheinrich C., Scharpf R., Wargenau M., et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethylstarch 130/0.4 (6%, 500 ml) in mild-to-severe renal impairment. Anesth Analg 95 (2002) 544-551
27. Kaur G., Hollingshead M., Holbeck S., et al. biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J 396 2 (2006) 235-242
28. Kim J.H., Kim Y.S., Park K., et al. Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 29 12 (2008) 1920-1930
29. Kubek M.J., Domb A.J., and Veronesi M.C. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles 6 2 (2009) 359-371
30. Kubek M.J., and Garg B.P. Thyrotropin-releasing hormone (TRH) in the treatment of intractable epilepsy. Pediatr Neurol 26 1 (2002) 9-17
31. ®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopaedic surgery than HES 200/0.5. Anesth Analg 92 (2001) 855-862
32. Liguori L., Marques B., Villegas-Mendez A., et al. Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins. J Control Rel 126 (2008) 21-27
33. Lilly C.M., Draxen J.M., and Shore S.A. Peptidase modulation of airway effects of neuropeptides. Proc Soc Exp Biol Med 203 (1993) 388-404
34. Lin L.F., Doherty D.H., Lile J.D., et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 5111 (1993) 1130-1132
35. Marazuela E.G., Prado N., Moro E., et al. Intranasal vaccination with poly(lactide-co-glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitisation. Clin Exp Allergy 38 3 (2008) 520-528
36. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42 6 (2003) 463-478
37. Nomura S., Inami N., Shouzu A., et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 20 1 (2009) 16-22
38. Pal S., Barnhart K.M., Wei Q., et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17 (1999) 459-465
39. Pal S., Peterson E.M., and de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 73 (2005) 8153-8160
40. Pal S., Theodor I., Peterson E.M., et al. Immunisation with the Chlamydia muridarum mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 69 (2001) 6240-6247
41. Patel Z.S., Ueda H., Yamamoto M., et al. In vitro and in vivo release of vascular endothelial growth factor from gelatine microparticles and biodegradable composite scaffolds. Pharm Res 25 10 (2008) 2370-2378
42. Patel Z.S., Yamamoto M., Ueda H., et al. Biodegradable gelatine microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta Biomater 4 5 (2008) 1126-1138
43. Riedel G.E., and Valentin-Opran A. Clinical evaluation of rhBMP-2/ACS in orthopaedic trauma: a progress report. Orthopaedics 22 7 (1999) 663-665
44. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
45. Sandmann A., Sasse F., and Muller R. Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity. Chem Biol 11 8 (2004) 1071-1079
46. Sasse F., Steinmetz H., Heil J., et al. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubule. Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 53 9 (2000) 879-885
47. Schluep T., Gunawan P., Ma L., et al. Polymeric tubulysin-peptide nanoparticles with potent antitumour activity. Clin Cancer Res 15 1 (2009) 181-189
48. Shaw J., Grund V., Durling L., et al. Dendritic cells pulsed with a recombinant Chlamydia major outer membrane protein antigen elicit a CD4+ type 2 rather than type 1 immune response that is not protective. Infect Immun 70 (2002) 1097-1105
49. Szpalski M., and Gunzburg R. Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft?. Acta Orthop Belg 71 2 (2005) 133-148
50. Tai M.H., Cheng H., Wu J.P., et al. Gene transfer of glial cell line-derived neurotrophic factor promotes functional recovery following spinal cord contusion. Exp Neurol 183 2 (2003) 508-515
51. Tauzin B. Report: biotechnology medicines in development (2008), Pharmaceutical Research and Manufacturers Association, Washington, DC
52. Thuret S., Moon L.D., and Gage F.H. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 7 8 (2006) 628-643
53. Wan R.Q., Noguera E.C., and Weiss S.R. Anticonvulsant effects of intra-hippocampal injection of TRH in amygdala kindled rats. Neuro-report 9 4 (1998) 677-682
54. Wang W. Instability, stabilisation and formulation of liquid protein pharmaceuticals. Int. J. Pharm 185 (1999) 129-188
55. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289 (2005) 1-30
56. Wang Y.C., Wu Y.T., Huang H.Y., et al. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 29 34 (2008) 4546-4553
57. Weissmann G., and Sessa G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res 9 3 (1968) 310-318
58. Werle M., and Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: development, characterisation and in vivo evaluation. Int J Pharm 370 1-2 (2009) 26-32
59. Wu X., Huang S., Zhang J., et al. Preparation and characterisation of novel physically cross-linked hydrogels composed of poly(vinyl alcohol) and amine-terminated polyamidoamine dendrimer. Macromol Biosci 4 (2004) 71-75
60. Zhang S., Doschak M.R., and Uludag H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. Biomaterials 30 28 (2009) 5143-5155
61. Zhang S., Wang G., Lin Z., et al. Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol Prog 24 4 (2008) 945-956
62. Ipsen Pharmaceuticals Limited, Decapeptyl S. R.-information for the patient. URL: http://www.ipsen.ie/dkp_patient.pdf.[Accessed 12/9/09].
63. Takeda UK Limited, Prostap 3 Leuprorelin acetate depot injection-summary of product characteristics. URL: http://emc.medicines.org.uk/document.aspx?documentId = 2237.[Accessed 12/9/09].